News

Indivior PLC announced that its U.S. affiliate, Indivior Inc., has launched an authorized generic version of SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) in the U.S. The…
Read More...

Torque, a clinical-stage immuno-oncology company developing first-in-class Deep Primed T Cell Therapeutics to direct immune power deep within the tumor microenvironment, announced that…
Read More...

Roche announced that the US Food and Drug Administration (FDA) has accepted the company’s New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for polatuzumab vedotin in…
Read More...

AbbVie has announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its New Drug Application (NDA) for upadacitinib for the treatment of adult…
Read More...

Pfizer Inc. and Eli Lilly and Company announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with moderate-to-severe chronic low back pain (CLBP). In…
Read More...

NEW ORLEANS & Ochsner Health System, Louisiana’s largest non-profit academic healthcare system, and Pfizer Inc have entered into a multi-year strategic alliance to develop…
Read More...

Aucta Pharmaceuticals announced that it has entered into an agreement with Oakrum Pharma, LLC (Oakrum) to develop and manufacture four prescription generic pharmaceutical products that…
Read More...

Exicure, Inc. and Dermelix Biotherapeutics announced a license and development agreement to advance SNA therapeutics in rare genetic skin diseases. Under the terms of agreement,…
Read More...

STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec, and BioLingus, a Swiss biotech company, announce they have formed an exclusive technology and marketing…
Read More...

Genentech announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for polatuzumab vedotin…
Read More...

Genentech announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Applications (NDAs) and granted Priority Review for entrectinib for the…
Read More...

Eli Lilly and Company announced the successful completion of its acquisition of Loxo Oncology. The acquisition broadens the scope of Lilly's oncology portfolio into precision medicines…
Read More...

Innovent Biologics announced the signing of a collaboration agreement with Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences) to evaluate the safety and tolerability of…
Read More...

Boehringer Ingelheim and Eli Lilly and Company announced CAROLINA (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) met its primary…
Read More...

Recipharm announced that all fifteen of its facilities outlined in its investment plan are now fully prepared for drug serialisation and have delivered serialised batches within Europe…
Read More...

Emerald Health Pharmaceuticals and Lonza have announced an agreement for the large-scale manufacturing of a new synthetic derivative of cannabidiol (CBD) and its oral drug product for…
Read More...

Merck, known as MSD outside the United States and Canada, announced the presentation of interim data from the Phase 1b/2 KEYNOTE-365 umbrella trial investigating KEYTRUDA, Merck’s…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) has approved Egaten (triclabendazole) for the treatment of fascioliasis in patients six years of age and older. This…
Read More...

AbCellera announced a multi-target and multi-year collaboration with Novartis. Under the agreement, AbCellera will apply its expertise in antibody discovery and its single-cell…
Read More...